Compo Biotech (Shanghai) Co., Ltd. launches phase I clinical study of KPG-121 in the treatment of advanced prostate cancer in the United States
Jun 29, 2018
Compo Biopharma Technology (Shanghai) Co., Ltd. ("Compo Biopharma") announced on June 27, 2018 that the phase I clinical trial of KPG-121, a Class I innovative drug independently developed by the company with global independent intellectual property rights, combined with enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) has been launched in the United States. This multi-center, open-label clinical study aims to evaluate the safety, tolerability, pharmacokinetic properties of KPG-121 and its preliminary anti-tumor effect in combination with enzalutamide. For more clinical study details, please see https://www.clinicaltrials.gov/ct2/show/NCT03569280.
About KPG-121
KPG-121 is a new generation of lenalidomide derivatives, a CRBN E3 ubiquitin ligase (E3 ubiquitin ligase) CRL4CRBN modulator. Preclinical study data show that compared with lenalidomide, KPG-121 has stronger immunomodulatory activity and more significant anti-angiogenic function. The results of multiple in vivo and in vitro biological studies have shown that KPG-121 can produce a strong synergistic effect against prostate cancer when combined with androgen receptor pathway modulators. Compared with enzalutamide, Abiraterone Acetate, Apalutamide or Darolutamide alone, the combination with KPG-121 can significantly improve the inhibitory activity and anti-tumor effect of prostate cancer cells. In addition, KPG-121 also has a highly effective inhibitory effect on multiple myeloma, myelodysplastic syndrome and other hematological tumors.
About Compo Biopharma
Compo Biopharmaceutical Technology (Shanghai) Co., Ltd., headquartered in Shanghai Zhangjiang High-Tech Park, is based on new generation protein ubiquitination and degradation technology platforms and focuses on the fields of cancer, autoimmune diseases and inflammation. It is committed to developing Class I innovative drugs with global independent intellectual property rights and insists on providing patients with the best treatment options. After several years of solid accumulation, Compo Biopharma has established a rich R&D pipeline in the treatment of prostate cancer, myelodysplastic syndrome, diffuse large B-cell lymphoma, multiple myeloma, mantle cell lymphoma, indolent cell lymphoma, systemic lupus erythematosus, psoriasis, arthritis and other fields. The company's overall strategic goal is to create a modern biopharmaceutical enterprise integrating R&D, production and sales to contribute to conquering diseases and improving human life and health.